TICAGRELOR AND MAJOR ADVERSE LIMB EVENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS

Authors :: Marc P. Bonaca
William R. Hiatt
Deepak L. Bhatt
Philippe Gabriel Steg
Connie N. Hess
Thomas A Zelniker
Marc S. Sabatine
Warren Cappell
Source :: Journal of the American College of Cardiology. 75:2246
Publication Year :: 2020
Publisher :: Elsevier BV, 2020.
Abstract: More potent anti-thrombotic strategies have been shown to reduce major adverse limb events (MALE) in patients with atherosclerosis. Ticagrelor is a potent P2Y12 inhibitor that reduces major adverse cardiovascular events (MACE) in stable patients with prior myocardial infarction and in those with